Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Ominsky

Showing results (41-50 of 81) with videos related to

Pageof 9
Sort By:
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|November 27, 2007
Skeletal deterioration induced by RANKL infusion: a model for high-turnover bone diseaseY Y Yuan, P J Kostenuik, M S Ominsky, et al.
Journal of Orthopaedic Research : Official Publication of the Orthopaedic Research Society|March 7, 2014
Evaluation of the effects of systemic treatment with a sclerostin neutralizing antibody on bone repair in a rat femoral defect modelFarhang Alaee, Mandeep S Virk, Hezhen Tang, et al.
Bone|May 4, 2019
Sclerostin antibody reduces long bone fractures in the oim/oim model of osteogenesis imperfectaMickaël Cardinal, Janne Tys, Thomas Roels, et al.
Calcified Tissue International|February 7, 2020
Sclerostin-Antibody Treatment Decreases Fracture Rates in Axial Skeleton and Improves the Skeletal Phenotype in Growing oim/oim MiceMickaël Cardinal, Alicia Dessain, Thomas Roels, et al.
Calcified Tissue International|May 10, 2008
Soluble RANKL induces high bone turnover and decreases bone volume, density, and strength in miceS A J Lloyd, Y Y Yuan, P J Kostenuik, et al.
Endocrinology|October 26, 2017
Sclerostin Antibody Reverses Bone Loss by Increasing Bone Formation and Decreasing Bone Resorption in a Rat Model of Male OsteoporosisXiaodong Li, Michael S Ominsky, Kelly S Villasenor, et al.
Bone|September 6, 2011
Increased callus mass and enhanced strength during fracture healing in mice lacking the sclerostin geneChaoyang Li, Michael S Ominsky, Hong-Lin Tan, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|November 20, 2008
Comparison of effects of the bisphosphonate alendronate versus the RANKL inhibitor denosumab on murine fracture healingLouis C Gerstenfeld, Daniel J Sacks, Megan Pelis, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|November 20, 2016
Romosozumab Improves Bone Mass and Strength While Maintaining Bone Quality in Ovariectomized Cynomolgus MonkeysMichael S Ominsky, Steven K Boyd, Aurore Varela, et al.
Regulatory Toxicology and Pharmacology : RTP|August 30, 2016
Carcinogenicity risk assessment of romosozumab: A review of scientific weight-of-evidence and findings in a rat lifetime pharmacology studyLuc Chouinard, Melanie Felx, Nacera Mellal, et al.
Pageof 9

Showing results (41-50 of 81) with videos related to

Sort By:
Pageof 9
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|November 27, 2007
Skeletal deterioration induced by RANKL infusion: a model for high-turnover bone diseaseY Y Yuan, P J Kostenuik, M S Ominsky, et al.
Journal of Orthopaedic Research : Official Publication of the Orthopaedic Research Society|March 7, 2014
Evaluation of the effects of systemic treatment with a sclerostin neutralizing antibody on bone repair in a rat femoral defect modelFarhang Alaee, Mandeep S Virk, Hezhen Tang, et al.
Bone|May 4, 2019
Sclerostin antibody reduces long bone fractures in the oim/oim model of osteogenesis imperfectaMickaël Cardinal, Janne Tys, Thomas Roels, et al.
Calcified Tissue International|February 7, 2020
Sclerostin-Antibody Treatment Decreases Fracture Rates in Axial Skeleton and Improves the Skeletal Phenotype in Growing oim/oim MiceMickaël Cardinal, Alicia Dessain, Thomas Roels, et al.
Calcified Tissue International|May 10, 2008
Soluble RANKL induces high bone turnover and decreases bone volume, density, and strength in miceS A J Lloyd, Y Y Yuan, P J Kostenuik, et al.
Endocrinology|October 26, 2017
Sclerostin Antibody Reverses Bone Loss by Increasing Bone Formation and Decreasing Bone Resorption in a Rat Model of Male OsteoporosisXiaodong Li, Michael S Ominsky, Kelly S Villasenor, et al.
Bone|September 6, 2011
Increased callus mass and enhanced strength during fracture healing in mice lacking the sclerostin geneChaoyang Li, Michael S Ominsky, Hong-Lin Tan, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|November 20, 2008
Comparison of effects of the bisphosphonate alendronate versus the RANKL inhibitor denosumab on murine fracture healingLouis C Gerstenfeld, Daniel J Sacks, Megan Pelis, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|November 20, 2016
Romosozumab Improves Bone Mass and Strength While Maintaining Bone Quality in Ovariectomized Cynomolgus MonkeysMichael S Ominsky, Steven K Boyd, Aurore Varela, et al.
Regulatory Toxicology and Pharmacology : RTP|August 30, 2016
Carcinogenicity risk assessment of romosozumab: A review of scientific weight-of-evidence and findings in a rat lifetime pharmacology studyLuc Chouinard, Melanie Felx, Nacera Mellal, et al.
Pageof 9